Benefits and Risks of Combining Anti-tumor Necrosis Factor with Immunomodulator Therapy in Pediatric Inflammatory Bowel Disease
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Benefits and Risks of Combining Anti-tumor Necrosis Factor with Immunomodulator Therapy in Pediatric Inflammatory Bowel Disease
Authors
Keywords
-
Journal
INFLAMMATORY BOWEL DISEASES
Volume 21, Issue 4, Pages 951-961
Publisher
Oxford University Press (OUP)
Online
2015-02-27
DOI
10.1097/mib.0000000000000245
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sa1204 Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- (2015) Walid M. Awni et al. GASTROENTEROLOGY
- Su1218 Concomitant Use of Immunomodulators Increases Long Term Response to Infliximab in Ulcerative Colitis - A Population-Based IBD-Sl Cohort Study
- (2015) Steven Jeuring et al. GASTROENTEROLOGY
- Sa1201 Pharmacokinetics of Adalimumab in Pediatric Patients With Moderate to Severe Crohn's Disease
- (2015) Doerthe Eckert et al. GASTROENTEROLOGY
- 833 Malignancies in Children Receiving Infliximab and Other Inflammatory Bowel Disease Therapies: An Inflammatory Bowel Disease Multicenter, Prospective, Long-Term Registry of Pediatric Patients (Develop) Registry Data
- (2015) Richard B. Colletti et al. GASTROENTEROLOGY
- A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
- (2014) B. G. Levesque et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry
- (2014) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Sa1153 Impact of Concomitant Immunosuppressant Use on Adalimumab Efficacy in Children With Moderately to Severely Active Crohn's Disease: Results From IMAgINE 1
- (2014) Jeffrey S. Hyams et al. GASTROENTEROLOGY
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- A 10-Year, Single Tertiary Care Center Experience on the Durability of Infliximab in Pediatric Inflammatory Bowel Disease
- (2014) Elaheh Vahabnezhad et al. INFLAMMATORY BOWEL DISEASES
- Infliximab Maintains Durable Response and Facilitates Catch-up Growth in Luminal Pediatric Crohnʼs Disease
- (2014) Peter C. Church et al. INFLAMMATORY BOWEL DISEASES
- Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis
- (2014) Uri Kopylov et al. Journal of Crohns & Colitis
- Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients
- (2014) Charlotte P. Peters et al. Journal of Crohns & Colitis
- Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
- (2014) F.M. Ruemmele et al. Journal of Crohns & Colitis
- Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis
- (2014) Michael J Hayes et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease
- (2013) Mark T. Osterman et al. GASTROENTEROLOGY
- Infliximab in Steroid-dependent Ulcerative Colitis
- (2013) Alessandro Armuzzi et al. INFLAMMATORY BOWEL DISEASES
- Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease
- (2013) Stephane Paul et al. INFLAMMATORY BOWEL DISEASES
- Ten Years of Infliximab for Crohn’s Disease
- (2013) Emma J. Eshuis et al. INFLAMMATORY BOWEL DISEASES
- Biological Therapy in a Pediatric Crohn Disease Population at a Referral Center
- (2013) Federica Nuti et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- A Pooled Analysis of Infections, Malignancy and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
- (2012) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study
- (2012) Parakkal Deepak et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
- (2012) Shomron Ben–Horin et al. Clinical Gastroenterology and Hepatology
- CD14+ intestinal macrophages contribute to the pathogenesis of Crohnʼs disease via IL-23/IFN-gamma axis.
- (2012) T Hisamatsu et al. INFLAMMATORY BOWEL DISEASES
- Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease
- (2012) Amit Assa et al. Journal of Crohns & Colitis
- Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome
- (2012) Orlando García-Bosch et al. Journal of Crohns & Colitis
- Management of Pediatric Ulcerative Colitis
- (2012) Dan Turner et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease
- (2011) R. K. Russell et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease
- (2011) Lisa J Herrinton et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience
- (2011) Michael B. Sprakes et al. Journal of Crohns & Colitis
- The duration of effect of infliximab maintenance treatment in paediatric Crohn’s disease is limited
- (2010) C. I. De Bie et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Nutritional Status and Growth in Pediatric Crohn's Disease: A Population-Based Study
- (2010) Francis Vasseur et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Outcome Following Infliximab Therapy in Children With Ulcerative Colitis
- (2010) Jeffrey S Hyams et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy
- (2010) H. Sokol et al. GUT
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials
- (2009) G. R. LICHTENSTEIN et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn’s Disease
- (2009) Joel R Rosh et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
- (2008) Gert Van Assche et al. GASTROENTEROLOGY
- Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
- (2008) F Schnitzler et al. GUT
- Long-term outcome of maintenance infliximab therapy in children with Crohnʼs disease
- (2008) Jeffrey S. Hyams et al. INFLAMMATORY BOWEL DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started